ANI Pharmaceuticals, Inc.

Is ANI Pharmaceuticals, Inc. technically bullish or bearish?

As of October 10, 2025, ANI Pharmaceuticals has a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite a bearish monthly RSI, and has significantly outperformed the S&P 500 year-to-date with a return of 62.43%.

As of 10 October 2025, the technical trend for ANI Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are mildly bullish, supporting a cautious upward outlook. However, the monthly RSI is bearish, suggesting some weakness in price strength. The Bollinger Bands show a bullish stance on the weekly and mildly bullish on the monthly, indicating potential for price movement within a positive range. The OBV is mildly bearish on the weekly but mildly bullish on the monthly, reflecting mixed volume trends.<BR><BR>In terms of performance, ANI Pharmaceuticals has outperformed the S&P 500 year-to-date with a return of 62.43% compared to the S&P 500's 11.41%, and over the past year, it has returned 62.96% versus the S&P 500's 13.36%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and KST indicators, despite some bearish signals from the RSI.

Is ANI Pharmaceuticals, Inc. overvalued or undervalued?

As of November 8, 2024, ANI Pharmaceuticals, Inc. is considered overvalued with a risky valuation grade, reflected by a Price to Book Value of 3.22, an EV to EBITDA ratio of 23.83, a negative ROE of -3.27%, and poor financial health compared to peers, despite recent stock performance.

As of 8 November 2024, ANI Pharmaceuticals, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued given its financial metrics, with a Price to Book Value of 3.22 and an EV to EBITDA ratio of 23.83, indicating significant valuation concerns. The company's ROE stands at -3.27%, reflecting ongoing losses and inefficiencies in generating returns for shareholders.<BR><BR>In comparison to its peers, ANI Pharmaceuticals shows a stark contrast, with its EV to EBITDA ratio of 23.83 being significantly higher than BioCryst Pharmaceuticals, which has an EV to EBITDA of 75.78, and Arcus Biosciences, which is at 0.0371. The overall financial health of ANI Pharmaceuticals, characterized by its negative P/E ratio and low ROCE of 0.14%, further supports the conclusion that the company is overvalued. Despite recent stock performance outpacing the S&P 500 over various periods, the underlying financial metrics suggest caution for potential investors.

How big is ANI Pharmaceuticals, Inc.?

As of Jun 18, ANI Pharmaceuticals, Inc. has a market capitalization of $1.38 billion, with net sales of $674.06 million and a net profit of -$22.62 million over the last four quarters. Shareholder's funds are $403.68 million, and total assets amount to $1.28 billion.

As of Jun 18, ANI Pharmaceuticals, Inc. has a market capitalization of 1,377.52 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 674.06 million, while the sum of net profit for the same period is -22.62 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 403.68 million and total assets of 1,283.70 million.

What does ANI Pharmaceuticals, Inc. do?

ANI Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription drugs. As of March 2025, it reported net sales of $197 million and a net profit of $14 million.

Overview: <BR>ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 197 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 14 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,377.52 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 1.18 <BR>Return on Equity: -3.27% <BR>Price to Book: 3.29<BR><BR>Contact Details: <BR>Address: 210 W Main St, BAUDETTE MN: 56623-2467 <BR>Tel: 1 218 6343500 <BR>Fax: 1 218 6343540 <BR>Website: http://www.anipharmaceuticals.com/

Who are in the management team of ANI Pharmaceuticals, Inc.?

As of March 2022, ANI Pharmaceuticals, Inc. is led by Chairman Patrick Walsh and CEO Nikhil Lalwani, with independent directors including Robert Brown, Thomas Haughey, David Nash, Thomas Penn, and Antonio Pera on the Board.

As of March 2022, the management team of ANI Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Patrick Walsh, Chairman of the Board<BR>- Mr. Nikhil Lalwani, President, Chief Executive Officer, and Director<BR><BR>Additionally, the Board of Directors features several independent directors: <BR><BR>- Mr. Robert Brown<BR>- Mr. Thomas Haughey<BR>- Dr. David Nash<BR>- Mr. Thomas Penn<BR>- Mr. Antonio Pera<BR><BR>This structure reflects a combination of executive leadership and independent oversight within the company.

Should I buy, sell or hold ANI Pharmaceuticals, Inc.?